Toxicogenetic studies of an antileishmania nanomedicine based on Ocotea fasciculata, a plant of the Brazilian flora

Autor(es)

Iara Silva Squarisi ^[1] ; Karoline Soares de Freitas ^[2] ; Heloiza Diniz Nicolella ^[3] ; Saulo Duarte Ozelin ^[4] ; José Maria Barbosa-Filho ^[5] ; Franciane Marquele-Oliveira ^[6] ; Andresa Aparecida Berretta ^[7] ; Denise Crispim Tavares ^[8]

Afiliação do(s) autor(es)

^[1] University of Franca - Brasil

^[2] University of Franca - Brasil

^[3] University of Franca - Brasil

^[4] University of Franca - Brasil

^[5] Federal University of Bahia. Faculty of Medicine of Bahia - Brasil

^[6] Apis Flora Indl. Coml. Ltda. Development and Innovation Laboratory - Brasil

^[7] Apis Flora Indl. Coml. Ltda. Development and Innovation Laboratory - Brasil

^[8] University of Franca - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Rodriguésia; v. 75, 2024-06-07.

Resumo

Abstract The lignoid fraction (LF) of Ocotea fasciculata, which is rich in yangambin and its epimer, epi-yangambin, showed promising activity against Leishmania sp. Subsequently, LF was incorporated into a solid lipid nanoparticle (SLN) in order to increase its pharmacological efficacy and decrease toxicity. In this regard, the present study was carried out to evaluate the cytotoxic and toxicogenetic potential of LF and LF-SLN in mammalian cells in vitro and in vivo. The cytotoxic activity was evaluated in a non-tumor human cell line (GM07492A) and the toxicogenetic potential was assessed in vitro in a Chinese hamster lung fibroblast cell line (V79) and in Swiss mice. LF-SLN showed no cytotoxic effect at the highest concentration tested (5,000 µg/mL), while LF exhibited an IC50 equivalent to 1,047 ± 4.50 µg/mL. The frequencies of micronuclei observed in vitro and in vivo in mammalian cells treated with different concentrations of LF and LF-SLN did not differ significantly from the negative control group. Therefore, LF and LF-SLN did not show genotoxic or cytotoxic effects under the experimental conditions used. These results contribute to the development of a drug for the treatment of leishmaniasis that is more effective and safer for human health. (AU)

• Processo FAPESP: 14/50410-3 - Desenvolvimento de um medicamento de base nanotecnológica oriundo da biodiversidade brasileira para tratamento de Leshmaniose
• Beneficiário: Franciane Marquele de Oliveira
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE
• Processo FAPESP: 11/51023-5 - O papel de transportadores de potássio bacterianos no processo de ativação do inflamassoma e na resposta de macrófagos a infecção por Legionella pneumophila
• Beneficiário: Juliana Issa Hori
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado